Infrastructure
[용어속성] Term
Chinese medicine for COVID-19 A protocol for systematic review and meta-analysis
3800
[키워드] 95% CIs
95% confidence interval
adverse effect
Analysis
appear
article
Asia
asymptomatic infection
cause
CBM
Chest CT
China
Chinese
Chinese medicine
CIs
CNKI
Cochrane Library
Consensus
continuous variable
Controlled trial
Coronavirus disease 2019
COVID-19
database
death
disagreement
disease
East
Efficacy
Efficacy and safety
Evidence
Handbook
hospitalised
include
Infrastructure
journal
literature
mean difference
Meta-analysis
Mild
Novel coronavirus
Nucleic acid detection
Odds ratio
outbreak
outcome
participant
Patient
performed
Placebo
Pneumonia
protocol
recruited
reported
resolved
Respiratory disease
Respiratory failure
Respiratory illness
Respiratory samples
Result
review
risk
risk of bia
Risk of bias
SARS-COV-2 infection
Science
searched
severe viral pneumonia
Spread
systematic review
technique
therapeutic agents
treat
Treatment
upper respiratory tract
variable
VIP
virus
with COVID-19
Wuhan, China
[DOI] 10.1097/MD.0000000000020660 PMC 바로가기 [Article Type] 3800
[DOI] 10.1097/MD.0000000000020660 PMC 바로가기 [Article Type] 3800
Efficacy and safety of Chinese patent medicine injection for COVID-19 A protocol for systematic review and meta-analysis
6700
[키워드] abstracts
attacked
bias risk
caused
China
Chinese
Chinese patent medicine injection
clinical symptom
clinical trial
Clinicians
Cochrane Library
Corona
country
COVID-19
database
Deterioration
Efficacy and safety
Epidemic
evaluate
Evidence
infection rate
Infrastructure
injection
journal
literature
Meta-analysis
outbreak
Patient
protocol
provided
Randomized controlled trial
reducing
researcher
shown
significant effect
systematic review
the disease
Treatment
virus infection
Web of Science
WHO
World Health Organization
[DOI] 10.1097/MD.0000000000020706 PMC 바로가기 [Article Type] 6700
[DOI] 10.1097/MD.0000000000020706 PMC 바로가기 [Article Type] 6700
Spread and Impact of COVID-19 in China: A Systematic Review and Synthesis of Predictions From Transmission-Dynamic Models
Medicine
[키워드] analysed
Analysis
article
basic reproduction number
CFR
China
Chinese
Coronavirus disease 2019
COVID-19
database
dropped
effective
effort
Evolution
fatality
global effort
Impact
Incubation
infected case
Infection
Infectious period
Infrastructure
Intervention
IQR
lockdown
mathematical
mathematical model
median
median size
Model
outbreak
pandemic
predict
prediction
reference
Reproduction number
review
screened
searched
secondary transmission
Spread
statistical model
sustained
synthesis
synthesised
systematic review
the epidemic
the reproduction number
Transmission
Web
Wuhan
Wuhan, China
[DOI] 10.3389/fmed.2020.00321 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2020.00321 PMC 바로가기 [Article Type] Medicine
The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19) A protocol for systematic review and meta analysis
3800
[키워드] adverse events
Analysis
Anxiety
appears
CBM
China
Chinese
clinical
clinical trial
CNKI
coronavirus disease
COVID-19
COVID-19, protocol
database
death
Efficacy and safety
evaluate
Evidence
exceeded
Fang
Google
Government
Infrastructure
Jinhua Qinggan Granule
journal
Meta-analysis
Novel coronavirus
number of infected
ongoing trial
patients with COVID-19
peer-reviewed
platform
Primary outcome
promoted
protocol
registry
secondary outcome
submitted
Symptom
syndrome
systematic review
TCM
Treatment
VIP
was used
Web of Science
[DOI] 10.1097/MD.0000000000020531 PMC 바로가기 [Article Type] 3800
[DOI] 10.1097/MD.0000000000020531 PMC 바로가기 [Article Type] 3800
Efficacy and safety of Jinhua Qinggan granules for coronavirus disease 2019 (COVID-19) A protocol of a systematic review and meta-analysis
3800
[키워드] acute respiratory syndrome
caused
CBM
China
Chinese
CNKI
coronavirus disease
Coronavirus disease 2019
COVID-19
database
determine
effective
Efficacy and safety
evaluated
Evidence
Fang
fatal disease
Granule
Infrastructure
Jinhua Qinggan granules
journal
Meta-analysis
Methodological quality
protocol
Registration
risk of bia
Stata
systematic review
treating COVID-19 patients
treatment for COVID-19
VIP
were used
[DOI] 10.1097/MD.0000000000020612 PMC 바로가기 [Article Type] 3800
[DOI] 10.1097/MD.0000000000020612 PMC 바로가기 [Article Type] 3800
Assessment of Chinese medicine for coronavirus-related pneumonia A protocol for systematic review and meta-analysis
4900
[키워드] 2019 novel coronavirus
2019 novel coronavirus disease
acute respiratory syndrome
adverse events
Analysis
analyzed
assessment
caused
China
Chinese
Chinese medicine
Chongqing
clinical trials
Cochrane Library
conducted
Continuous data
database
diagnosed
disease
Effect
Efficacy and safety
Egger test
Evidence
funnel plot
global pandemic
hospital
identify
include
Infrastructure
intensive care units
Mantel–Haenszel
mean difference
mechanical ventilation
Meta-analysis
methodology
Middle East
morbidity and mortality
Mortality
outcome
pandemic
performed
Pneumonia
Primary outcome
protocol
provided
Randomized controlled trial
reported
risk ratio
Sample size
searched
Severe acute respiratory syndrome
SinoMed
syndrome
systematic review
Treatment
trial sequential analysis
type I
VIP
[DOI] 10.1097/MD.0000000000020613 PMC 바로가기 [Article Type] 4900
[DOI] 10.1097/MD.0000000000020613 PMC 바로가기 [Article Type] 4900
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
Article
[키워드] ACE2, angiotensin converting enzyme II
ACE2angiotensin converting enzyme II
activities
acute respiratory distress syndrome
Adverse reactions
angiotensin converting enzyme II
ARDS, acute respiratory distress syndrome
ARDSacute respiratory distress syndrome
articles
Biological
Biological products
C-reactive protein
cellular
Characteristics
Chemical drugs
China
China National Knowledge Infrastructure
Chinese
chronic obstructive pulmonary disease
clinical trial
clinical trials
CNKI
CNKI, China National Knowledge Infrastructure
CNKIChina National Knowledge Infrastructure
convalescent plasma
COPD, Chronic obstructive pulmonary disease
COPDchronic obstructive pulmonary disease
Coronavirus disease 2019
COVID-19
COVID-19, Coronavirus disease 2019
COVID-19coronavirus disease 2019
CP, convalescent plasma
CPconvalescent plasma
CRP, C-reactive protein
CRPC-reactive protein
database
dengue virus
DENV, dengue virus
DENVdengue virus
drug
drugs
EC50, half effective concentration
EC50half effective concentration
effective drugs
Effects
Efficacy and safety
Fangfeng Tongsheng Pill
FFTS, Fangfeng Tongsheng Pill
FFTSFangfeng Tongsheng Pill
filtered
GA, glycyrrhizic acid
GAglycyrrhizic acid
glycyrrhizic acid
Government
half effective concentration
Health
HIV, Human immunodeficiency virus
HIVhuman immunodeficiency virus
HSBD, Huashi Baidu Prescription
HSBDHuashi Baidu Prescription
Huashi Baidu Prescription
Human immunodeficiency virus
Huoxiang Zhengqi
HXZQ, Huoxiang Zhengqi
HXZQHuoxiang Zhengqi
IFN-α, interferon-α
IFN-αinterferon-α
indications
Infrastructure
ingredient
injection
Interferon-α
JHQG, Jinhua Qinggan Granule
JHQGJinhua Qinggan Granule
Jiedu Capsule
Jinhua Qinggan Granule
large sample
LHQW, Lianhua Qingwen Capsule
LHQWLianhua Qingwen Capsule
Lianhua Qingwen capsule
medication
MERS-CoV, Middle East respiratory syndrome coronavirus
MERS-CoVmiddle east respiratory syndrome coronavirus
Mesenchymal stem cells
Middle East respiratory syndrome Coronavirus
MNV, murine norovirus
MNVmurine norovirus
MSCs, mesenchymal stem cells
MSCsmesenchymal stem cells
murine norovirus
natural killer
NCP, novel coronavirus pneumonia
NCPnovel coronavirus pneumonia
NK, natural killer
NKnatural killer
Novel coronavirus
novel coronavirus pneumonia
pharmacological
Pneumonia
Potential
QFPD, Qingfei Paidu Decoction
QFPDQingfei Paidu Decoction
Qingfei Paidu decoction
Randomized controlled trials
RCTs, randomized controlled trials
RCTsrandomized controlled trials
researcher
respiratory syncytial virus
ribofuranosyl-5′-triphosphate
RSV, respiratory syncytial virus
RSVrespiratory syncytial virus
RTP, ribofuranosyl-5′-triphosphate
RTPribofuranosyl-5′-triphosphate
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
SARS-CoV, severe acute respiratory syndrome coronavirus
SARS-CoVsevere acute respiratory syndrome coronavirus
searched
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
Shufeng SFJD, Jiedu Capsule
Shufeng SFJDJiedu Capsule
stem cells
TCM
TCMs, traditional Chinese medicines
TCMstraditional Chinese medicines
therapeutic effect
TJQW, Toujie Quwen Granule
TJQWToujie Quwen Granule
Toujie Quwen granule
Traditional Chinese medicine
traditional Chinese medicines
treat
Treatment
Vaccines
XFBD, Xuanfei Baidu Decoction
XFBDXuanfei Baidu Decoction
Xuanfei Baidu Decoction
[DOI] 10.1016/j.virusres.2020.198057 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.virusres.2020.198057 PMC 바로가기 [Article Type] Article
The effect of massage on the quality of life in patients recovering from COVID-19 A systematic review protocol
4700
[키워드] acupuncture therapy
anorexia
article
average
Chest
China
Chinese
Controlled
Convalescent patients
COVID-19
curative
database
diarrhea
disease
distress
Dyspnea
effective intervention
English
Evidence
headache
Hospitalization
Increases
Infrastructure
literature
massage
myalgia
nausea
outbreak of COVID-19
outcome
Patient
pharyngalgia
postoperative
protocol
Quality of life
Randomized controlled trial
recovering from COVID-19
researcher
secondary
subject
Symptom
systematic review
therapy
vomiting
Web of Science
[DOI] 10.1097/MD.0000000000020529 PMC 바로가기 [Article Type] 4700
[DOI] 10.1097/MD.0000000000020529 PMC 바로가기 [Article Type] 4700
Psychological intervention on COVID-19 A protocol for systematic review and meta-analysis
4900
[키워드] 95% confidence interval
Admission
adverse events
calculated
change
Chinese
CIs
clinical
clinical heterogeneity
Cochrane Library
cough
COVID-19
database
Dyspnea
effective
Effectiveness
Effects
Efficiency
Evidence
expressed
GAD-7
Hamilton Anxiety Scale
independent
Infrastructure
Intervention
journal
literature
mean difference
Meta-analysis
Mild
Non-invasive
Novel coronavirus infection
outcomes
Patient
PHQ-9
physical
positive
Primary outcomes
protocol
psychological condition
Psychological intervention
random effect model
randomised controlled trial
registry
reported
requiring supplemental oxygen
researcher
risk
RT-PCR
scale
searched
Secondary outcomes
SMD
standardized mean difference
suggested
systematic review
time
Treatment
upper respiratory tract
used to evaluate
Web of Science
WHO
[DOI] 10.1097/MD.0000000000020335 PMC 바로가기 [Article Type] 4900
[DOI] 10.1097/MD.0000000000020335 PMC 바로가기 [Article Type] 4900